Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their erythroid response, particularly in patients with high endogenous erythropoietin (EPO) level, and may improve other cytopenias. We conducted a prospective multicenter study of EPO-b and ATRA in anemic MDS patients with marrow blasts o10% and either previous ESA failure or relapse, endogenous EPO 4500 U/l or other cytopenia(s) (absolute neutrophilic count o1.0 G/l or platelets o50 G/l). A total of 59 patients were evaluable after 12 weeks of treatment. The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n ¼ 28): 43 and 32%; patients with endogenous EPO 4500 U/l (n ¼ 18): 11 and 19%; patients transfused 42 red blood cells units/month (n ¼ 28) 43 and 39%. Only one neutrophil, but no platelet response, and no major side effect were observed. EPO-b-ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia.
Introduction
Most myelodysplastic syndromes (MDS) are anemic and require red blood cell (RBC) transfusion support during the disease course.
1 Anemia reduces quality of life of MDS patients, but also survival, especially by increasing cardiovascular morbidity and mortality, 2 and by transfusion-induced iron overload. 3 Anemia of MDS responds to erythropoiesis-stimulating agents (ESAs) alone and combined to granulocyte-colony-stimulating factor (G-CSF) in 20% and in 40% of unselected MDS, respectively. [4] [5] [6] Response rates reach 60% in MDS with low baseline serum erythropoietin (EPO) level (o200-500 U/l), low transfusion requirement (o2 RBC/month) and low or intermediate-1 IPSS. 7, 8 Thus ESAs, with or without G-CSF, are considered first-line treatments of anemia of MDS with low and intermediate-1 IPSS (except in patients with 5q deletion, where lenalidomide is more effective). 9 All-trans retinoic acid (ATRA) is a vitamin A derivative involved in normal hematopoiesis, particularly in terminal granulocytic differentiation. 10 In MDS, retinoids given as single agent [11] [12] [13] [14] or combined with various drugs, including valproic acid, 15, 16 interferon-a, 17 vitamin E derivatives, 18 vitamin D derivatives or androgens, 19 yield modest improvements in cytopenias, especially anemia.
In vitro studies have shown that combination of ATRA with recombinant EPO (r-EPO) can induce erythroid differentiation. 20 In a series of 27 patients, the combination of r-EPO and ATRA yielded erythroid response in 13 of them. 21 Endogenous EPO level was not predictive of erythroid response, suggesting that addition of ATRA could overcome EPO resistance. 21 Furthermore, some patients experienced multilineage response, as previously described with ATRA alone. 16, 22 To confirm those findings in a larger number of patients, the Groupe Francophone des Myelodysplasies (GFM) designed a prospective multicenter phase II clinical trial combining EPO-b and ATRA in patients with MDS with less than 10% bone marrow blasts.
Patients and methods

Patients
Inclusion criteria were (1) age 18 years or older, (2) MDS with less than 10% marrow blasts and anemia (defined as hemoglobin (Hb) concentration o10 g per 100 ml for at least 2 months or requiring at least 2 RBCs transfusion units in the previous 2 months), (3) one or several of the following criteria:
(i) additional cytopenia(s) (absolute neutrophilic count (ANC) o1.0 G/l and/or platelets o50 G/l), (ii) endogenous EPO level 4500 UI/l or (iii) previous ESA failure, defined as refractoriness or relapse according to IWG 2000 criteria 23 after a wellconducted ESA trial, that is, r-EPO at X30 000 U/week or darbepoetin-a at X150 mg per week for at least 12 weeks. Exclusion criteria were (1) estimated creatinine clearance o30 ml/min; (2) severe cardiac, pulmonary, neurologic, digestive or genitourinary disease unrelated to MDS; (3) chemotherapy during the previous 3 months; (4) chronic myelomonocytic leukemia or marrow blasts 410%; (5) Eastern Cooperative Oncology Group (ECOG) score of 4; (6) iron, vitamin B12 or folic acid deficiency; (7) systemic hypertension (systolic arterial pressure higher than 160 mm Hg); (8) life expectancy of less than 6 months; and (9) pregnant and breast feeding women. In agreement with Helsinki's Declaration, this study was approved by an independent ethical committee, and all patients signed an informed consent form. This trial is registered at www.clinicaltrials.gov as no. NCT00437450.
Treatment
Patients received epoetin-b (NeoRecormon 20 000 UI Â 3/week, Roche, Basel, Switzerland) in combination with ATRA (45 mg/m 2 /day, every other week, Vesanoid, Roche) for 12 weeks. All responders (HI-E minor and major according to the IWG 2000 criteria) were to continue the treatment for another 12 weeks; dose escalation of ATRA to 80 mg/m 2 /day (every other week) was allowed in patients failing to reach HI-E major. There was no planned extension phase in the trial. Roche Pharma, France, provided study drugs and a research grant for this trial.
Study evaluations
Baseline evaluation included patient history and physical examination, peripheral blood count, bone marrow aspiration with cytogenetics, standard chemistry including liver and renal function tests and serum EPO level. Patients were reassessed every 2 weeks during the duration of treatment, with transfusion and toxicity history, physical examination, peripheral blood counts and chemistry. The bone marrow aspirate was repeated at 12 and 24 weeks.
Response criteria
All patients treated for at least 12 weeks were considered evaluable. Erythroid response, assessed by IWG 2000 criteria (including major erythroid responseFHI-E majorFand minor erythroid responseFHI-E minor 23 ) served as primary end point and for treatment modification. Responses were subsequently reassessed according to the revised IWG 2006 criteria. 24 Neutrophil (HI-N) and platelet response (HI-P) were also assessed according to the IWG 2000 criteria in all patients with ANC o1.5 G/l and/or platelets o100 G/l, and not only in patients entered in the study with ANC o1.0 G/L or platelets o50 G/l. The secondary end point was safety. Toxicities were graded according to the NCI Common Toxicity Criteria, version 3.0.
Statistical analysis
Data were reported as number and percentages, or median and ranges.
Prognostic factors of response, including FAB and WHO classification, IPSS, karyotype, pretreatment serum EPO level and transfusion requirement were analyzed using Wilcoxon rank-sum test for continuous variables and Fisher's exact test for bivariate comparisons. P-values o0.05 were considered significant. All tests were two-sided.
Results
Baseline characteristics of the patients
Sixty-five patients from 23 centers meeting inclusion criteria were entered between October 2004 and April 2005. Six of them did not complete 12 weeks of treatment because of concomitant breast cancer diagnosis (n ¼ 1), testis cancer suspicion (n ¼ 1), death due to infection (n ¼ 2), cardiac failure (n ¼ 1) and progression to higher risk MDS (n ¼ 1), and were considered inevaluable. All those events occurred during the first 4 weeks of treatment and were considered unrelated to the protocol.
The remaining 59 patients, all evaluable at 12 weeks, were characterized by previous resistance to an ESA treatment in 28 (48%), endogenous EPO level 4500 U/l in 18 (30%) and additional cytopenias (ANC o1.0 G/l or platelets o50 G/l) in 34 (58%) patients. Among the 28 patients with resistance to an ESA (26 primary failures and 2 HI-E minor followed by relapse), 18 and 10, respectively had endogenous EPO o500 and 4500 U/l, while 23 of the patients were included based on the sole presence of additional cytopenias.
Baseline characteristics of the 59 patients are presented in Table 1 . Median age was 68 years (range 24-91). According to WHO classification, the population included 16 RA, 18 RARS, 19 RAEB-1, two 5qÀ syndrome, 1 refractory cytopenia with multilineage dysplasia and 1 unclassified MDS. In addition to the two cases of 5qÀ syndrome, eight other patients had del 5q, with excess of marrow blasts in seven cases, and one or several additional chromosomal aberrations in three patients. Two patients were retrospectively reclassified as RAEB-2 (with 11 and 13% blasts) upon marrow review. Baseline characteristics of the 18 patients with resistance to an ESA and EPO level o500 U/l are shown in Table 2a , and those of the 23 patients included in the trial based on the sole presence of additional cytopenias are shown in Table 2b . All patients in the latter group were ESA naive, with a median EPO level of 125 U/l (range 16-465).
Erythroid response
In the 59 patients who received epoetin-b in combination with ATRA for at least 12 weeks, the overall response rate was 49% (29/59), with 14 HI-E major (24%) and 15 HI-E minor (25%) ( Table 3) . Transfusion independence was achieved in 10 of the 43 patients transfusion-dependent at baseline (23%). Using IWG 2006 criteria, the response rate was 36% (21/59). Response was achieved at 12 weeks in all responders. Dose escalation of ATRA to 80 mg/m 2 /day, performed after 12 weeks in 19 patients (including 6 minor HI-E and 13 non-responders at 45 mg/m 2 / day) converted only one minor HI-E to major HI-E and did not r-EPO ATRA combination in low risk MDS R Itzykson et al yield any additional response in patients who did not respond at 45 mg/m 2 /day. Twenty of the 29 responders continued treatment until week 24: their response was stable in 17 responders (85%), while 3 (1 HI-E major and 2 minor at 12 weeks) relapsed. Reason for trial discontinuation in the remaining nine responders was progression (n ¼ 1), febrile neutropenia (n ¼ 1), grade 2 skin and liver toxicity attributable to ATRA (n ¼ 1) and patient or physician's decision without objective sign of toxicity (n ¼ 6), including three ESA naive patients who were continued on EPO alone because there was no effect on other cytopenias, two HI-E minor who were switched after 12 weeks to thalidomide (n ¼ 1) and androgens (n ¼ 1) because clinical benefit of HI-E was judged insufficient, and one patient with HI-E major who decided of trial discontinuation after 20 weeks. Continuation of treatment beyond week 24 was left to physicians decision, and most responders were continued on r-EPO alone.
Of the 28 patients who had previously failed to achieve erythroid response with an ESA alone, 12 (43%) responded as per IWG 2000 criteria (including 14% HI-E major and 29% HI-E minor) and 9/28 (32%) as per IWG 2006 criteria. Among them, the 18 patients with EPO level o500 U/l had a 11/18 (61%) overall IWG 2000 response rate including four (22%) HI-E major and seven (39%) HI-E minor. The IWG 2006 response rate in this group was 7/18 (39%).
On the other hand, none of the 18 patients with endogenous serum EPO level 4500 U/l achieved major HI-E and only 2 (11%) reached HI-E minor, corresponding to two responses (11%) as per IWG 2006 criteria. Both responders required transfusion of more than 2 RBC concentrates per month at inclusion. In 28 patients with high transfusion needs (42 RBC/ month), the IWG 2000 response rate was 43% (four and eight HI-E major and minor, respectively), and the IWG 2006 response rate was 39% (11/28). In 12 patients with both EPO level 4500 U/l and transfusion need 42 RBC/month, two (17%) minor HI-E (IWG 2000) and two responses by IWG 2006 were observed. In the 23 ESA naive patients with EPO level o500 U/l included because of additional cytopenias, there were 16/23 (70%, including nine major and seven minor) and 12/23 (52%) responses according to IWG 2000 and 2006 criteria, respectively. Finally, the response rate in the 10 patients with del 5q was 3/10 with IWG 2000 criteria (one HI-E major, two HI-E minor) and 3/10 with 2006 criteria.
Other cytopenias
None of the 20 patients with platelet counts o100 G/l treated by epoetin-b-ATRA combination reached HI-P as per IWG 2000 or ). On the other hand, previous ESA failure (P ¼ 0.44) and transfusion need 42 RBC units/month (P ¼ 0.44) had no negative impact on response to epoetin-b-ATRA combination. Results were similar when considering IWG 2006 criteria (not shown).
Side effects of epoetin-b-ATRA combination
Side effects of epoetin-b-ATRA combination are summarized in Table 4 . No grade 4 toxicity was observed. Grade 3 toxicities included muscle pain (n ¼ 1), elevated liver enzymes without hepatic failure (n ¼ 1) and fatigue (n ¼ 2). All other toxicities were grade 1 or 2, the most frequent being headaches (32%), dry skin (46%) and dry mucosa (39%). Four patients (7%) had disease progression during epoetin-b-ATRA treatment: two patients with RAEB-1 (one with -Y, the other with del 5q and del 7q) progressed to RAEB-2; two patients with RAEB-1 (and isolated del 5q) and RA (with complex karyotype), respectively, progressed to RAEBt (FAB)/AML (WHO). Infection occurred in Table 2b Baseline characteristics of patients included because of additional cytopenias n % 27 46 18  31  9  15  Muscular pain  2  3  1  2  1  2  Bone pain  5  8  5  8  Fatigue  2  3  2  3  Elevated AST or ALT 11 19  5  8  5  8  1  2  Elevated creatinine  1  2  1  2  Infection  2  3  1  2  1  2  Febrile neutropenia  3  5  1  2  2  3 Abbreviation: ATRA, all-trans retinoic acid. On the other hand, we observed only 11% erythroid responses in patients with baseline EPO level 4500 U/l compared with 50% in the report of Stasi et al. 21 Also contrasting with Stasi et al.'s results, epoetin-b and ATRA combination therapy did not result in significant neutrophil and platelet improvement in our study. This discordance does not appear to be due to the higher starting dose of ATRA in the study of Stasi et al. (80 vs 45 mg/m 2 in our study), as dose escalation to the same dosage in our cohort after 12 weeks of treatment did not improve neutrophil or platelet counts.
The response rate we observed in patients with previous failure or relapse after an ESA alone appears comparable to those obtained in this situation with thalidomide, 25 lenalidomide, 26 azacitidine 27 and antithymocyte globulin alone. 28 In patients resistant to an ESA alone, its combination with G-CSF or GM-CSF also yields 20-40% erythroid responses. 6, [29] [30] [31] [32] [33] However, ESA-G-CSF combinations give disappointing results in patients with high endogenous EPO levels, 7 similar to what we observed with the epoetin-b-ATRA combination.
No extension phase beyond week 24 was planned in our study, and most patients continued with epoetin alone, so that long-term efficacy and tolerance of the epoetin-b-ATRA combination could not be evaluated.
Finally, epoetin-b-ATRA combination was well tolerated, with a toxicity profile similar to that described with ATRA alone. Four cases of disease progression occurred, including two cases of progression to RAEBt (FAB)/AML (WHO), but those patients all had an excess of marrow blasts and/or unfavorable karyotype at inclusion.
The disappointing results of epoetin-b-ATRA combination in patients with high endogenous EPO levels, and the limited activity of ATRA as single agent on erythroid responses in previous studies suggest that ATRA may improve anemia of lowrisk MDS in synergy with r-EPO rather than by an independent mechanism. This model is in line with previous in vitro findings 34 and may be similar to that described with G-CSF, 35 as those two drugs appear to share common in vitro properties in MDS cell lines. 36 It would therefore be of interest to compare the efficacy of r-EPO-ATRA and r-EPO-G-CSF combinations.
Thus, epoetin-b-ATRA combination yields significant erythroid response rates in low-risk MDS patients having failed r-EPO or unlikely to respond to r-EPO because of high transfusion needs. Those results warrant further confirmatory randomized studies in these patients. However, alternative treatments are required in patients with high endogenous EPO levels and/or other cytopenias.
